| Today's Big NewsOct 17, 2022 |
|
Greater Philadelphia offers bioscience companies space to develop in close proximity to its world-class University City research center and global airport. From production to R&D, learn how the region can be your launchpad for growth and expansion. 
|
|
| By Eric Sagonowsky,Angus Liu,Fraiser Kansteiner,Zoey Becker,Kevin Dunleavy What a difference five years—and a global pandemic—can make in reshaping an industry. Our latest profile of the top vaccine players includes twice the number of companies as last time along with a handful of new names. |
|
|
|
By Nick Paul Taylor Sage Therapeutics and Biogen have shared a closer look at phase 3 data on zuranolone in postpartum depression, presenting secondary endpoint results from SKYLARK while racing to wrap up a filing for FDA approval. |
By Healthcare Staff Follow along with the latest news and insights from the Fierce Healthcare team on the fallout from the Supreme Court's Dobbs decision. |
By Andrea Park Monday marked the first day that some hearing aids may be sold over the counter, without requiring any prescriptions, hearing tests or fitting appointments, thanks to a recently finalized—and long-awaited—ruling from the FDA. |
By Fraiser Kansteiner When a long-awaited FDA hearing over Covis Pharma’s recurrent preterm birth drug Makena kicked off Monday, the agency paraded out a half dozen of its experts to convince the panel it should recommend withdrawal of the medicine. |
By Conor Hale The company said it hopes its "future-ready" Omni Legend system will set the stage for the imaging modality for next 10 to 20 years. |
By Gabrielle Masson As SPAC deals in biotech make a slow comeback, another merger has been penned, this time between Swiss biotech Oculis and European Biotech Acquisition Corp. |
By Heather Landi Retail drugstore giant Walgreens is bullish on scaling up its primary, post-acute and home care businesses as part of its long-term strategy to become a consumer-centric healthcare company. On the heels of a recent buying spree, the company may be eyeing a health technology acquisition as its next strategic play. |
By Max Bayer MacroGenics' decision to pivot its focus to its asset MGD024 appears to have paid off, with Gilead pledging up to $1.7 billion in biobucks for the phase 1 bispecific antibody. |
By Kevin Dunleavy In 2014, when Johnson & Johnson broke ground on an ambitious manufacturing facility in India and announced its plan to employ 1,500, local dignitaries hailed the initiative and its promise to bring major development to a rural area near Hyderabad. Eight years later, the company has sold the site without ever conducting operations there. |
By Dave Muoio Last year saw 27 private equity deals in the medical staffing space, representing 21.1% of the sector's total deal volume, according to data cited in a new report from nonprofit Private Equity Stakeholder Project. |
By Gabrielle Masson As NGM Biopharmaceuticals’ phase 2 trial misses the mark, dreams for its macular degeneration treatment may be disappearing from sight. |
By Andrea Park All eyes are on Eyenuk, now that the Los Angeles-based startup has more than doubled its lifetime fundraising haul and set its sights on bringing AI-powered diagnostic tools to even more diseases and conditions. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our latest analysis on the world’s most productive biopharmas. We also discuss Biogen's tumultuous year and who it is considering for a new CEO. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now. 
|
|
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
